Dr. Kyle Kopicki Named One of Pottstown's Leading Chiropractors by Local Patients
Dr. Kyle Kopicki has been named one of Pottstown, PA and Limerick, PA top chiropractors, a recognition driven by glowing patient reviews and life-changing results. Known for his integrity, custom care plans, and consistent outcomes, Dr. Kopicki treats everything from back pain to sports injuries. With over 100 five-star reviews, his clinic thrives on reputation, not hype. New patients are welcome to experience the difference at Keep It Kinetic Chiropractic. Learn more at kikchiro.com
Pottstown, PA - May 27, 2025 - In a powerful testament to trust, consistency, and life-changing results, Dr. Kyle Kopicki has been named one of Pottstown & Limerick, PA top chiropractors — a recognition earned not through self-promotion, but from the most meaningful source of all: his own patients.
This community-driven recognition highlights what patients have long known — that Dr. Kopicki stands out not just for his clinical skill, but for the care, integrity, and outcomes he delivers every single day. With over a hundred 5-star reviews, ongoing referrals, and a reputation that continues to grow organically, Dr. Kopicki is becoming synonymous with effective, honest, patient-first chiropractic care in the region.
From back and neck pain to sports injuries, migraines, sciatica, and wellness maintenance, Dr. Kopicki's ability to get results where others fall short is a major reason why patients travel from all across Montgomery County to seek his care.
'My family and I have been seeing Dr. Kyle for years and have loved our experience with him!' — Juliana B.
'Dr. Kyle and the rest of the team are fantastic! My family and I will continue to come here regularly as we always leave feeling amazing!' — Emma R.
At a time when trust in healthcare providers is more important than ever, testimonials like these paint a clear picture: Dr. Kopicki doesn't just treat symptoms — he earns trust. Whether it's a new mom recovering from pregnancy, a postal worker dealing with repetitive strain, or a high school athlete aiming to get back on the field, the clinic's success stories span generations and lifestyles.
His practice is grounded in evidence-based protocols, full spine assessments, and customized treatment plans that evolve as the patient progresses. No one-size-fits-all solutions. No unnecessary long-term treatment plans. Just straightforward care, focused on getting people out of pain and back to living.
'I have been going to Dr. Kyle for years now. Not only is he helping prolong my career by keeping my body aligned and out of pain. He is one of the most personable docs you'll come across. His staff is always kind and smiles on their faces. Always a great experience!' — Vickie E.
'I've been seeing Dr. Kopicki for a few years now and he is awesome. He has vast knowledge about many modalities. Staff are very personable and caring. Highly recommend!' — Lisa T.
A Clinic Built on Results, Not Hype
What sets Dr. Kopicki apart isn't a flashy ad or a marketing campaign. It's reputation. It's real people telling real stories about how they got their lives back. His clinic's online reviews reflect a pattern: patients consistently mention how seen, heard, and respected they feel — and how quickly they start noticing improvements.
This recognition as one of Pottstown's leading chiropractors is more than a label — it's a reflection of the clinic's deep roots in the community and the lives that have been changed along the way.
Dr. Kopicki continues to welcome new patients who are ready to experience chiropractic care done right. If you've been told to 'just live with it,' it's time to get a second opinion.
MEDIA CONTACT
Keep It Kinetic Chiropractic
3254 W Ridge Pike
Suite 202
Pottstown, PA 19464
Call (484) 455-4664
Visit https://www.kikchiro.com/ to book your consultation today.
Media Contact
Company Name: Keep It Kinetic Chiropractic
Contact Person: Dr. Kyle Kopicki
Email: Send Email
Phone: (484) 455-4664
Address: 3254 W Ridge Pike Suite 202
City: Limerick
State: PA
Country: United States
Website: https://kikchiro.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Dr. Brian Day predicted the health care mess we're in today
Last month, it was revealed that between 2018 and 2024, almost 142,000 people walked out of an emergency room in British Columbia without being seen by a doctor or a nurse. The numbers make up just some of the data tracked by the province's health ministry. The information was obtained by the BC Conservative Party via a freedom-of-information request because heavens knows these are not the kind of statistics a sitting government wants out there – especially a government that has fought hard to maintain the status quo when it comes to health care in the province. 'It's just really sad that this is what passes for a quality health care system,' Dr. Brian Day says to me over the phone. 'The numbers are shocking, and yet we've seen this coming for years now.' Certainly he has. I've been chronicling Dr. Day's fight against the health care system as we know it for years. And I can say, unequivocally, that he forecast the sorry state of affairs we are living today, with long waits for important surgeries becoming a part of daily life for far too many Canadians. Dr. Day predicted emergency rooms would not have the capacity to meet the growing number of people in Metro Vancouver unless the government went on a major hiring spree. Successive administrations didn't listen, and here we are today. In rural B.C., frequent ER closings show how 'fragile' the health care system has become B.C. health authority cuts dozens of jobs after quiet government directive to balance budget There are few doctors in this country who have been as high-profile and controversial as Dr. Day has been for three decades. He has been the tireless pitchman for a hybrid system of health care that allows for some private providers, like the clinic he's operated in Vancouver for three decades. The journey he's been on has now been chronicled in his new autobiography: My Fight For Canadian Healthcare: A Thirty-Year Battle To Put Patients First. It is a meticulous piece of work with more than 500 references to data and research he says grounds his position in the facts. I would urge all defenders of the great system we have today to spend some time exploring its pages. It's impossible to not come away flummoxed and angry at the gross hypocrisy of those who continue to support a system that perennially underperforms against our peer nations – despite, in many cases, spending far more money. The book walks the reader through Dr. Day's long fight with the B.C. government to allow private health insurance in the province. The struggle, of course, ultimately led to a defeat in B.C. Supreme Court in 2020, with the judge in the case rejecting Dr. Day's argument that British Columbians had a constitutional right to access private care when wait times in the public system put a person's health and life at risk. Ultimately, the Supreme Court of Canada refused to hear an appeal. This would be the same court that in 2005 ruled that private insurance could be allowed in Quebec because, in the words of then-chief justice Beverley McLachlin, 'access to a waiting list is not access to health care.' So private health care is allowed in Quebec, just not anywhere else in Canada. Make that make sense. The ruling against Mr. Day's clinic only applied to B.C. and its residents. So, people in Alberta, for instance, who are tired of waiting for knee or hip surgery there, can come to Dr. Day's clinic and pay to get help. (And they do.) Just as British Columbians tired of being in pain here can go to a private clinic in Alberta and get operated on. (As they do as well.) 'Many Canadians don't realize it, but we're the only country on the planet where most people are prevented from getting private health insurance,' Dr. Day told me. But Ottawa does allow people to have private insurance for things like drug prescriptions. So, again, no private insurance allowed to get diagnosed with a health problem, but it's okay to have it for the drugs needed to remedy your issue. Again, if you can make that make sense, good for you. Dr. Day is 78 years old now and still performing surgeries. He is as animated as ever on the topic of Canadian health care, especially on social media, where he showcases the absolute insanity of the system we live under in his many posts. As he points out in his book, there is nothing like it in the world. 'I think I'm being proven right in terms of the warnings I sounded years ago,' Dr. Day said. 'I do believe that some day people will come to their senses and realize a hybrid model where some private health care is allowed makes sense – which is why all the best health care systems have it.'
National Post
24 minutes ago
- National Post
CitiusTech Acquires Health Data Movers, Enhances Healthcare Provider Offerings With Epic Implementation Capabilities
Article content PRINCETON, N.J. — CitiusTech, a leading provider of healthcare technology, services & solutions, today announced that it has acquired Health Data Movers, a Best in KLAS healthcare technology services firm, with deep expertise in Epic Systems, Workday, ServiceNow and other core healthcare platforms. Article content As healthcare providers work to improve quality of care and deliver more connected patient and clinician experiences, they face the challenges of unifying complex technology ecosystems while accelerating innovation. The rapid rise of Agentic AI, Cloud, and AI Scribes has only heightened the need for seamless integration into the core systems clinicians and staff use every day. Epic, as the digital backbone of many healthcare providers, has been central to this transformation, driving digital adoption, enabling interoperability, and opening new pathways to embed advanced analytics and AI directly into clinical workflows. Article content The combination of CitiusTech's AI, data, and automation solutions and Health Data Movers' deep integration expertise, creates a unique ability to embed intelligence and automation directly into core operational platforms such as EMR, ITSM and ERP. By bringing advanced digital capabilities directly into the daily workflows that health systems trust, this approach minimizes change management risks, and delivers scalable, end-to-end solutions that enable Providers to achieve greater efficiency, quality, and impact in patient care. Article content 'This is a pivotal moment and huge opportunity for CitiusTech and Health Data Movers, as we meet the demands of a rapidly transforming healthcare landscape. By combining forces, we are redefining the path to seamless integration, and infusing AI and intelligent automation into clinical operations. Together, we empower our customers to unlock transformative efficiencies, deliver connected patient care, and accelerate innovation, all within the systems they trust. This partnership strengthens CitiusTech's position as a strategic partner across the healthcare ecosystem,' said Rajan Kohli, CEO, CitiusTech. By bringing Health Data Movers' Epic implementation and integration expertise into CitiusTech's portfolio, this partnership has the ability to operate at the very core of the Epic ecosystem, solving some of healthcare's most critical challenges. Article content 'At Health Data Movers, our commitment has always been to empower patients and providers by harnessing the potential of data and technology,' said Tyler Smith, CEO, Health Data Movers. 'Joining forces with CitiusTech allows us to pair that expertise with unmatched scale, advanced technologies, and expanded capabilities. Together, we can deliver future-ready solutions, that not only improve patient outcomes and lower costs, but also redefine how patients and providers fully benefit in an AI-powered healthcare ecosystem.' Article content CitiusTech and Health Data Movers share a vision of advancing healthcare through human-centered technology, operational excellence, and trusted partnerships. Article content Founded in 2012, Health Data Movers is a US-based, specialized healthcare IT services firm, with a mission to empower patients and Providers by unleashing the potential of healthcare data and technology. They are trusted partners to healthcare organizations, biotechnology companies, and digital health enterprises, delivering unique, data-driven solutions through their Data Management, Integration, Project Management and Clinical & Business Applications services. Health Data Movers brings with it a highly skilled team of healthcare technology professionals with deep expertise in large-scale EMR program delivery, clinical workflows, and operational transformation. Article content Health Data Movers was advised on this transaction by Equiteq. Article content About CitiusTech Article content CitiusTech Article content is a global technology services, consulting, and business solutions enterprise 100% focused on the healthcare and life sciences industry. We enable 140+ enterprises to build a human-first ecosystem that is efficient, effective, and equitable. Leveraging deep domain expertise and next-generation technologies including AI, Cloud, Data, and Intelligent Automation, we assist our clients in realizing their vision, accelerate transformation, and achieve business outcomes. With over 8,500 healthcare technology professionals worldwide, CitiusTech powers digital innovation, business transformation, and industry-wide convergence through next-generation technologies, solutions, and products. Follow CitiusTech on Article content . Article content Health Data Movers Article content (HDM) is a 'Best in KLAS' healthcare technology services firm. They are trusted partners to healthcare organizations, biotechnology companies, and digital health enterprises through their Services – Data Management, Integration, Project Management, and Clinical & Business Applications – they are the smart choice for creating unique solutions that empower patients and providers by unleashing the potential of healthcare data and technology. Recognized as a leader in the industry, HDM has been named to the Inc. 5000 list six times (2020, 2021, 2022, 2023, 2024, 2025). Additionally, HDM was honored as one of the 'Best Firms to Work For' by Consulting Magazine in 2020 and 2025. Article content Article content Article content
Globe and Mail
28 minutes ago
- Globe and Mail
Diabetic Retinopathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Diabetic Retinopathy Pipeline Insights 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook Key Takeaways from the Diabetic Retinopathy Pipeline Report On August 18, 2025 (Monday), findings published online in JAMA Ophthalmology (August 14 edition) revealed that semaglutide therapy in adults with diabetes does not raise the risk of developing eye disorders or diabetic retinopathy. On August 15, 2025, Eyepoint Pharmaceuticals Inc. carried out a randomized, double-masked clinical trial assessing the ocular safety and efficacy of two different doses of the EYP-1901 IVT insert, compared with a sham treatment. On August 18, 2025, Genentech Inc. initiated a clinical trial designed to investigate both ocular and systemic safety, tolerability, and efficacy of RO7446603 in patients with diabetic macular edema (DME). The study includes two main parts: Phase I (Parts 1–4), which examined the safety of single and multiple intravitreal (IVT) doses as monotherapy or in combination with IVT aflibercept or IVT faricimab (administered separately), and Phase II (Part 5) for further evaluation. DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment. The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment Diabetic Retinopathy Emerging Drugs Profile Tarcocimab tedromer: Kodiak Sciences Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (""ABC"") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy. OTT166: Ocuterra Therapeutics Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy. APX3330: Apexian Pharmaceuticals APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy. OTX-TKI: Ocular Therapeutix OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy. The Diabetic Retinopathy Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment. Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs Diabetic Retinopathy Companies Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives Scope of the Diabetic Retinopathy Pipeline Report Coverage- Global Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective Table of Content Introduction Executive Summary Diabetic Retinopathy: Overview Pipeline Therapeutics Therapeutic Assessment Diabetic Retinopathy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) KSI-301: Kodiak Sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) RGX 314: Regenxbio Inc Drug profiles in the detailed report….. Early Stage Products (Phase I) OTX-TKI: Ocular Therapeutix Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetic Retinopathy Key Companies Diabetic Retinopathy Key Products Diabetic Retinopathy- Unmet Needs Diabetic Retinopathy- Market Drivers and Barriers Diabetic Retinopathy- Future Perspectives and Conclusion Diabetic Retinopathy Analyst Views Diabetic Retinopathy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
